Business
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the significant clinical and commercial progress achieved over recent months.
About this update from Volitionrx Limited
[{"type":"text","content":"HENDERSON, Nev., Feb. 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the significant clinical and commercial progress achieved over recent months.","length":284,"tagName":"p"},{"type":"text","content":"Key Highlights:","length":15,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Capture-Seq™ Platform: Paper recently submitted for peer review, underscores a $23 billion[1] annualized opportunity in cancer detection.","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Lung Cancer: Reimbursement submission in France on track; routine clinical use expected by Q4 2026.","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Veterinary Breakthrough: 100% specificity achieved in Feline Lymphoma study; $5M milestone payment anticipated.","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Sepsis & NETosis Validation: Inclusion of the Nu.Q® NETs assay in the $7.3 million government-backed DETECSEPS program in France.","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"Licensing Momentum: Company confirms active discussions with ~10 global diagnostic leaders.","length":96,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":596,"olType":false},{"type":"text","content":"Capture-Seq™ Breakthrough in Cancer Detection.","length":46,"tagName":"p"},{"type":"text","content":"We were delighted to submit for peer review a manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy." This paper showcases both a new method, Capture-Seq™, and new biomarkers for the detection of cancer, holding the promise of accurate, low-cost tests for a wide range of cancers.","length":421,"tagName":"p"},{"type":"text","content":"This scientific breakthrough has generated a lot of interest with potential licensing partners. We feel that this technology could, with further development, become very widely used and are actively seeking large commercial partner/s to work with us to accelerate the integration and launch of this technology as soon as possible.","length":330,"tagName":"p"},{"type":...